Arab Journal of Urology (2017) **xxx**, xxx–xxx

Arab Journal of Urology
(Official Journal of the Arab Association of Urology)

www.sciencedirect.com

ORIGINAL ARTICLE

Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial

Md Jawaid Rahman, M. Shazib Faridi *, Naloh Mibang, Rajendra Sinam Singh

Department of Urology, Regional Institute of Medical Sciences, Imphal, Manipur, India

Received 26 July 2017, Received in revised form 2 November 2017, Accepted 14 November 2017

KEYWORDS

Efficacy;
Silodosin;
Tadalafil;
Tamsulosin;
Ureteric calculi

ABBREVIATIONS

AR, adrenergic receptor;
cGMP, cyclic guanosine monophosphate;
KUB, kidney, ureter, and bladder;
MET, medical expulsive therapy;
PDE(-5), phosphodiesterase (type 5);
USG, ultrasonography

Abstract ***Objective:*** To compare the efficacy of tamsulosin, silodosin, and silodosin plus tadalafil as medical expulsive therapy (MET) for distal ureteric calculi.

Methods: In all, 120 patients who met the inclusion criteria were randomised into one of three treatment arms: tamsulosin (Group A), silodosin (Group B), and silodosin plus tadalafil (Group C). The drugs were given for a maximum of 4 weeks. The primary endpoint was the stone expulsion rate and secondary endpoints were stone expulsion time, number of pain episodes, and side-effects associated with MET. The follow-up period was for 4 weeks, after which ureteroscopic lithotripsy was done to remove any stones that were not expelled.

Results: There was a statistically significantly higher stone expulsion rate in Group C (90%) as compared to groups A (57.5%) and B (77.5%) with a shorter mean time to stone expulsion. Also, there were statistically fewer pain episodes in Group C as compared to groups A and B. There were no serious side-effects.

Conclusion: The present study concludes that the combination of silodosin and tadalafil increases the ureteric stone expulsion rate and decreases the expulsion time significantly. This combination provided significantly better control of pain without any serious side-effects.

Introduction

Urolithiasis is one of the most common urological diseases and affects 5–10% of people globally [1]. In all, 20% of all urinary tract stones are ureteric in location, and ~70% are found in the lower one-third of the ureter

* Corresponding author.
E-mail address: drshazibfaridi@gmail.com (M.S. Faridi).

Peer review under responsibility of Arab Association of Urology.

Production and hosting by Elsevier

https://doi.org/10.1016/j.aju.2017.11.012

Please cite this article in press as: Rahman MJ et al. Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial, *Arab J Urol* (2017), https://doi.org/10.1016/j.aju.2017.11.012

[2]. There has been a steep rise in minimally invasive procedures [3] but medical expulsive therapy (MET) is still regarded as an established treatment option for the management of distal ureteric stones. Stone location, size, number, ureteric spasm, mucosal oedema or inflammation, and ureteric anatomy are the factors affecting passage of ureteric stones [4]. Reported spontaneous passage rates for distal ureteric stones of < 5 mm range from 71% to 98% and for stones measuring 5–10 mm from 25% to 53% [5]. Even though the stones pass in most cases, they can cause acute pain to the patient whilst passing down the ureter. So, there is a further need for agents that promote better stone passage with reduced need for surgical interventions.

In MET, passage of the stone is facilitated by relaxation of ureteric smooth muscle, a decrease in the ureteric mucosal oedema, and an increase in the hydrostatic pressure proximal to the stone. There are abundant α_1-adrenergic receptors (ARs) in the distal third of ureteric smooth muscle. These receptors when blocked inhibit basal smooth muscle tone and hyperperistaltic uncoordinated frequency, whilst maintaining tonic propulsive contractions [6]. Ureteric spasms due to stones interfere with calculi expulsion. Thus, tamsulosin an α_1-adrenergic receptor blocker causes ureteric muscle relaxation with maintenance of normal antegrade peristaltic activity that facilitates the passage of stones [2].

Phosphodiesterases (PDEs) regulate intracellular cyclic nucleotide turnover influencing smooth muscle tension. PDE-5 inhibitors, such as sildenafil or tadalafil, act via the nitric oxide/cyclic guanosine monophosphate (cGMP)-signalling pathway, resulting in increased levels of cGMP, which leads to ureteric smooth muscle relaxation [7]. The AUA as well as the European Urological Association ureteric stones clinical guidelines support the use of MET for patients with distal ureteral calculi of < 10 mm. In comparison with surgical intervention for ureteric stones, MET has a high safety profile and low cost [8].

Silodosin is a more selective α_{1A}-adrenergic receptor antagonist than tamsulosin and has a better stone expulsion rate than tamsulosin [9]. Tadalafil, a PDE-5 inhibitor used alone or combined with tamsulosin is safe, efficacious, and well tolerated for the treatment of lower ureteric stones [10]. Tadalafil was used in place of sildenafil as it is associated with less visual problems and as its absorption does not appear to be affected by meals [11].

The combination of silodosin and tadalafil has greater potency than either drug alone for the treatment of LUTS associated with BPH [12], but no study has been reported using these two drugs in combination for the treatment of lower ureteric stones.

Therefore, we decided to perform a prospective randomised study to evaluate the role of combined silodosin and tadalafil in comparison with proven silodosin and tamsulosin individually for ureteric stone expulsion.

Patients and methods

This was a prospective study conducted at a tertiary care centre in the north eastern part of India. It was conducted from August 2014 to July 2015 after obtaining Institutional Ethics Committee clearance. Inclusion criteria were: Patients aged $\geq$18 years with a distal ureteric stone of 5–10 mm in greatest dimension diagnosed by full bladder ultrasonography (USG) of the kidney, ureter, and bladder (KUB) or X-ray KUB; if patient's pain subsided in 1 day with 75 mg diclofenac (i.m.); and the patient was prepared to enrol in the study. Exclusion criteria were: UTI, severe hydroureteronephrosis, multiple ureteric stones, solitary kidney, renal insufficiency, previous therapies for the stone, history of open surgery/endoscopic interventions, concomitant treatment with calcium antagonists, β-blockers, corticosteroids or nitrates; ureteric strictures, pregnant or lactating mothers, and those who refused to enrol in the study.

In all, 135 patients were enrolled in the study, of which 120 patients met the inclusion criteria. After providing written and informed consent, patients were randomised into three equal groups based on computer generated random number table. Group A was given tamsulosin 0.4 mg once daily, those in Group B were given silodosin 8 mg once daily, and those in Group C were given a combination of silodosin 8 mg with tadalafil 5 mg once daily (Fig. 1). In all the groups, drugs were continued until stone expulsion or for a maximum period of 4 weeks. All patients were assessed by physical examination, serum creatinine levels, urine culture, and USG KUB or X-ray KUB when required. Along with the allocated drug, patients were advised to take plenty of fluids and tablet diclofenac 50 mg orally during pain episodes. Patients were followed-up for 4 weeks, after which ureteroscopic lithotripsy was used to remove any stones that had not been expelled. The primary endpoint was the stone expulsion rate and secondary endpoints were stone expulsion time, rates of interventions such as ureterorenoscopy, number of pain episodes, and side-effects associated with MET. The stone expulsion time was defined as the number of days from the random allocation to the expulsion of stone and expulsion of stone was confirmed by USG KUB or X-ray KUB.

Comparison of all three groups for normally distributed data was performed using ANOVA. Group wise comparison of data was done by z-score. A $P < 0.05$ was considered to be statistically significant and the power used was 0.80. The required sample size per group was 40. The Statistical Package for the Social

Please cite this article in press as: Rahman MJ et al. Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial, *Arab J Urol* (2017), https://doi.org/10.1016/j.aju.2017.11.012